An antitrust review is a formal examination conducted by government agencies—primarily the Federal Trade Commission (FTC) and Department of Justice (DOJ) in the U.S.—to determine whether a business transaction or practice violates antitrust laws. These laws protect market competition and prevent monopolistic behavior. When you invest in a company planning a merger, acquisition, or expansion, an antitrust review may be required before the deal can close.
How It Works
The process typically begins when companies notify regulators about a proposed merger or acquisition. Agencies assess whether the transaction would substantially reduce competition in any market. They examine factors like market share, barriers to entry, customer impact, and whether rivals could effectively compete post-deal. The review can range from a simple clearance to a detailed investigation lasting months or even years. In some cases, agencies challenge deals in court or impose conditions—such as divestitures or operational restrictions—as a price for approval.
Why It Matters for Investors
Antitrust risk directly impacts your returns. A deal you thought would close in six months might face regulatory delays, increasing costs and uncertainty. Worse, a blocked transaction can sink valuations overnight. Companies in concentrated industries—tech, pharma, telecommunications—face higher scrutiny. As an investor, you need to assess antitrust exposure early: Can your portfolio company acquire targets without regulatory issues? Could a buyer face antitrust obstacles when acquiring your company? These questions shape exit timelines and valuations significantly.
Example
Imagine you invested in a regional software company competing against three larger players. When a strategic buyer offers to acquire your portfolio company, both parties assume a straightforward 90-day close. However, the buyer already controls 35% market share in that segment. If the combined entity would reach 55%, regulators likely challenge the deal. The FTC opens a full investigation, extends timelines to nine months, and ultimately requires the buyer to divest certain product lines. Your exit gets delayed, transaction costs balloon, and deal value erodes. This scenario plays out regularly in concentrated markets.
Key Takeaways
- Antitrust reviews protect market competition and can block or delay acquisitions and mergers
- High market concentration and industry consolidation increase regulatory scrutiny risk
- Early antitrust assessment helps investors understand exit risks and timeline uncertainties
- Regulatory conditions or divestitures can materially reduce deal value and investor returns